Our Infection Control Practitioner has approached us regarding changing the brand of chlorhexidine patch we use on all central lines. We have routinely used the Ethicon BioPatch while keeping a few Bard GuardIVa on hand for those lines that ooze. However, she has found that with our purchasing program the GuardIVa are much cheaper and wants to switch. My concerns with this are:
- exposing every patient to Bard's "propriatary hemostatic agent"
- the notable difference in the amout of Chlorhexine (I believe it is 24mg vs 92mg)
- lastly, the lack of research on Bard's part showing their patch "was not clinically tested for its activity to reduce local infections, CRBSI, or skin colonization of microorganisms commonly related to CRBSI" (on GuardIVa box).
Any information would be greatly appreciated, especially published studies (hard to find) before we make a decisions.